NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer

This publication has 45 references indexed in Scilit:

• ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers
  Proceedings of the National Academy of Sciences, 2014
• Pathology and Diagnosis of Neuroendocrine Tumors
  Thoracic Surgery Clinics, 2014
• Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
  Science, 2014
• Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
  2014
• Treatment of Small Cell Lung Cancer in Academic and Community Settings
  The Cancer Journal, 2014
• The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
  Nature Biotechnology, 2012
• Polymerase reaction without primers throughout for the reconstruction of full-length cDNA from products of rapid amplification of cDNA ends (RACE)
  Biotechnology Letters, 2011
• Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube
  Developmental Biology, 2009
• Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
  Cancer Research, 2008
• Mutational analysis of the neurexin/neuroligin complex reveals essential and regulatory components
  Proceedings of the National Academy of Sciences, 2008